Huiqing Xu

Huiqing Xu

Auto-generated profile, based on publicly available information

Huiqing Xu

Nanjing Municipal Center for Disease Control and Prevention, Affiliated Nanjing Medical University, Nanjing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in British Journal of Dermatology
Verified
Journal Article
Closed access
JWJiahe Wei
Jiahe Wei
JZJiahao Zhu
Jiahao Zhu
HXHuiqing Xu
Huiqing Xu
DZDan Zhou
Dan Zhou
JEJames T. Elder
James T. Elder
YLYingjun Li
Yingjun Li

25 August 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
HXHuiqing Xu
Huiqing Xu
YLYuxiao Ling
Yuxiao Ling
HJHan Jiang
Han Jiang
YLYingjun Li
Yingjun Li
JMJiang Minmin
Jiang Minmin
Background: Observational studies indicate that osteoarthritis (OA) and coronary artery disease (CAD), as well as myocardial infarction (MI), are often diagnosed as comorbid diseases. We performed a bidirectional Mendelian randomization (MR) study to demonstrate whether there is a causal relationship between OA, CAD, and MI.Methods: We extracted single nucleotide polymorphisms (SNPs) related to OA in the Genetics of Osteoarthritis (GO) Consortium as instrumental variables to assess whether OA is associated with CAD and MI in the CARDIoGRAMplusC4D 1,000 Genomes genome-wide association study (GWAS). In the reverse MR, we used CAD-associated and MI-associated SNPs to the GWAS of OA to analyze their causality. These GWASs included 766,690 individuals of OA, 184,305 individuals of CAD, and 166,065 individuals of MI. MR was conducted using several methods, including the inverse variance weighted (IVW) method, the weighted median method, the MR-Egger method, and the MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) method.Results: The forward causal effect of OA on CAD and MI was not observed. In reverse analysis, no causal effect was discovered for CAD on the risk of OA. Notably, we observed a causal association between MI and total OA [IVW odds ratio (OR) = 0.95, 95% CI = 0.93, 0.98, P = 4E−04] and spine OA (IVW OR = 0.92, 95% CI = 0.88, 0.97, P = 0.001) but a null association between MI and knee OA, hip OA, hand OA, and thumb OA.Conclusion: This MR study identifies a potentially protective effect of genetically predicted MI on total and spine OA risks.

30 September 2026 in Journal of Preventive Medicine and Public Health
Verified
Journal Article
Open access
PDF file
XDXiaojing Deng
Xiaojing Deng
HXHuiqing Xu
Huiqing Xu
YBYeping Bian
Yeping Bian
YXYunting Xu
Yunting Xu
GAGuofeng Ao
Guofeng Ao
FXFei Xu
Fei Xu
Objectives: Heart failure (HF), a common comorbidity of chronic obstructive pulmonary disease (COPD), is associated with an increased risk of death among patients with COPD. However, no systematic assessment has quantified the population-level burden of comorbid COPD and HF, worldwide. This study assessed the global, regional, and national HF burden attributable to COPD from 1990 to 2021 and projected this burden to 2050.Methods: Data on the non-fatal burden of COPD-attributable HF, including prevalence and years lived with disability (YLDs), were obtained from the Global Burden of Disease Study 2021. Temporal trends in age-standardized rates (ASRs) for COPD-attributable HF from 1990 to 2021 were examined using joinpoint models. Bayesian age-period-cohort models were used to project ASRs to 2050.Results: From 1990 to 2021, the absolute numbers of prevalent cases and YLDs for COPD-attributable HF increased globally, and the ASRs for prevalence and YLDs also increased. These upward trends were projected to continue to 2050. The burden of HF attributable to COPD was consistently higher in males than in females and higher in older adults than in younger individuals. By severity level, the burden of HF attributable to COPD was mainly driven by the treated and severe subtypes of HF. The burden varied substantially across regions, with low-socio-demographic index regions had the highest age-standardized burden.Conclusions: The global non-fatal burden of HF attributable to COPD was substantial from 1990 to 2021 and may continue to increase to 2050. Public health interventions targeting HF attributable to COPD may help reduce this burden.